NASDAQ:SMMT - Summit Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.17 -0.05 (-0.38 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$13.17
Today's Range$12.9691 - $13.30
52-Week Range$8.80 - $16.86
Volume11,969 shs
Average Volume32,442 shs
Market Capitalization$183.02 million
P/E Ratio-17.56
Dividend YieldN/A
Beta0.8

About Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics logoSummit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939

Debt

Debt-to-Equity RatioN/A
Current Ratio1.89
Quick Ratio1.89

Price-To-Earnings

Trailing P/E Ratio-17.56
Forward P/E Ratio-5.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.07 million
Price / Sales5.05
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book14.16

Profitability

EPS (Most Recent Fiscal Year)($0.75)
Net Income$-9,280,000.00
Net Margins-30.89%
Return on Equity-146.46%
Return on Assets-18.23%

Miscellaneous

Employees40
Outstanding Shares13,840,000

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics (NASDAQ:SMMT) issued its quarterly earnings results on Wednesday, April, 11th. The company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.34. The business earned $4.27 million during the quarter, compared to analyst estimates of $4.91 million. Summit Therapeutics had a negative return on equity of 146.46% and a negative net margin of 30.89%. View Summit Therapeutics' Earnings History.

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, June, 13th 2018. View Earnings Estimates for Summit Therapeutics.

What price target have analysts set for SMMT?

7 brokers have issued 1 year price targets for Summit Therapeutics' stock. Their predictions range from $20.00 to $33.00. On average, they anticipate Summit Therapeutics' share price to reach $27.00 in the next year. View Analyst Ratings for Summit Therapeutics.

Who are some of Summit Therapeutics' key competitors?

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the folowing people:
  • Mr. Glyn O. Edwards MBE, Chief Exec. Officer and Exec. Director (Age 62)
  • Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
  • Prof. Kay Davies FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
  • Prof. David Roblin BSc, MBBS, FRCP, MFPM, Chief Operating Officer, Chief Medical Officer and Pres of R&D (Age 51)
  • Ms. Michelle Avery, Director of Investor Relations

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Has Summit Therapeutics been receiving favorable news coverage?

Headlines about SMMT stock have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Summit Therapeutics earned a news sentiment score of 0.22 on Accern's scale. They also gave news articles about the company an impact score of 48.29 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (5.42%), Millennium Management LLC (0.17%) and Royal Bank of Canada (0.09%). View Institutional Ownership Trends for Summit Therapeutics.

Which institutional investors are selling Summit Therapeutics stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Point72 Asset Management L.P.. View Insider Buying and Selling for Summit Therapeutics.

Which institutional investors are buying Summit Therapeutics stock?

SMMT stock was bought by a variety of institutional investors in the last quarter, including Royal Bank of Canada. View Insider Buying and Selling for Summit Therapeutics.

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $13.17.

How big of a company is Summit Therapeutics?

Summit Therapeutics has a market capitalization of $183.02 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Summit Therapeutics employs 40 workers across the globe.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX14 4RY. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]


MarketBeat Community Rating for Summit Therapeutics (SMMT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  300
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Summit Therapeutics (NASDAQ:SMMT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Summit Therapeutics in the last 12 months. Their average twelve-month price target is $27.00, suggesting that the stock has a possible upside of 105.01%. The high price target for SMMT is $33.00 and the low price target for SMMT is $20.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00$26.20$26.00
Price Target Upside: 105.01% upside104.08% upside142.59% upside114.34% upside

Summit Therapeutics (NASDAQ:SMMT) Consensus Price Target History

Price Target History for Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics (NASDAQ:SMMT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$27.00HighView Rating Details
4/24/2018HC WainwrightSet Price TargetBuy$20.00MediumView Rating Details
4/12/2018Needham & Company LLCLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00MediumView Rating Details
2/13/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$33.00HighView Rating Details
1/26/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $30.00HighView Rating Details
1/4/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$24.00LowView Rating Details
10/16/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
11/16/2016Royal Bank of CanadaBoost Price TargetOutperform$26.00 ➝ $29.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Summit Therapeutics (NASDAQ:SMMT) Earnings History and Estimates Chart

Earnings by Quarter for Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics (NASDAQ:SMMT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.14)
2019 EPS Consensus Estimate: ($3.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.65)($0.65)($0.65)
Q2 20181$1.15$1.15$1.15
Q3 20181($0.73)($0.73)($0.73)
Q4 20182($0.91)($0.90)($0.91)
Q1 20192($0.98)($0.75)($0.87)
Q2 20192($0.85)($0.77)($0.81)
Q3 20192($1.05)($0.84)($0.95)
Q4 20192($1.25)($0.98)($1.12)

Summit Therapeutics (NASDAQ SMMT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/13/2018        
4/11/2018Q4 2018($0.81)($1.15)$4.91 million$4.27 millionViewListenView Earnings Details
12/6/2017Q3 2018($0.73)($0.20)$2.32 million$2.29 millionViewN/AView Earnings Details
8/31/20177/31/2017$1.38$1.10$31.37 million$25.01 millionViewN/AView Earnings Details
6/14/2017Q1 2018($0.65)($0.50)$2.29 million$2.24 millionViewN/AView Earnings Details
3/29/2017Q4 2017($0.71)($0.50)$0.07 million$2.18 millionViewN/AView Earnings Details
12/15/2016Q3 2017($0.80)($0.45)$0.15 million$0.70 millionViewN/AView Earnings Details
9/8/2016Q2 2017($0.69)($0.65)$0.34 million$0.02 millionViewN/AView Earnings Details
6/2/2016Q1 2017($0.64)($0.65)$0.36 million$0.09 millionViewN/AView Earnings Details
5/10/2016Q4 2016($0.55)ViewN/AView Earnings Details
12/17/2015Q3 2016($0.08)($0.60)$0.39 million$0.58 millionViewN/AView Earnings Details
8/27/2015Q215($0.06)($0.55)$0.39 million$0.67 millionViewListenView Earnings Details
6/11/2015Q115($0.06)($0.45)$0.39 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Summit Therapeutics (NASDAQ:SMMT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Summit Therapeutics (NASDAQ SMMT) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 28.13%
Insider Trading History for Summit Therapeutics (NASDAQ:SMMT)
Institutional Ownership by Quarter for Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics (NASDAQ SMMT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Summit Therapeutics (NASDAQ SMMT) News Headlines

Source:
DateHeadline
Summit Therapeutics (SMMT) Expected to Post Quarterly Sales of $6.48 MillionSummit Therapeutics (SMMT) Expected to Post Quarterly Sales of $6.48 Million
www.americanbankingnews.com - May 20 at 3:06 AM
 Brokerages Anticipate Summit Therapeutics (SMMT) to Post -$0.76 EPS Brokerages Anticipate Summit Therapeutics (SMMT) to Post -$0.76 EPS
www.americanbankingnews.com - May 18 at 1:43 PM
Summit Therapeutics (SMMT) Receives Consensus Recommendation of "Buy" from BrokeragesSummit Therapeutics (SMMT) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 9 at 3:28 AM
Sarepta Therapeutics: The Art Of Rallying Off Of Bad NewsSarepta Therapeutics: The Art Of Rallying Off Of Bad News
seekingalpha.com - May 7 at 4:23 PM
Zacks: Brokerages Expect Summit Therapeutics (SMMT) Will Announce Quarterly Sales of $7.02 MillionZacks: Brokerages Expect Summit Therapeutics (SMMT) Will Announce Quarterly Sales of $7.02 Million
www.americanbankingnews.com - May 3 at 5:49 AM
Summit Therapeutics (SMMT) Lifted to Buy at ValuEngineSummit Therapeutics (SMMT) Lifted to Buy at ValuEngine
www.americanbankingnews.com - May 2 at 6:12 PM
Summit Therapeutics (SMMT) Now Covered by Analysts at Janney Montgomery ScottSummit Therapeutics (SMMT) Now Covered by Analysts at Janney Montgomery Scott
www.americanbankingnews.com - May 2 at 11:28 AM
 Analysts Expect Summit Therapeutics (SMMT) to Announce -$0.81 EPS Analysts Expect Summit Therapeutics (SMMT) to Announce -$0.81 EPS
www.americanbankingnews.com - May 1 at 1:10 AM
Summit Therapeutics (SMMT) Given a $20.00 Price Target at HC WainwrightSummit Therapeutics (SMMT) Given a $20.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 24 at 11:34 AM
3 Things In Biotech, April 23: Support, Support, And Those Blasted Blood Vessels3 Things In Biotech, April 23: Support, Support, And Those Blasted Blood Vessels
seekingalpha.com - April 24 at 9:40 AM
Summit Therapeutics (SMMT) Upgraded to Hold at Zacks Investment ResearchSummit Therapeutics (SMMT) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 19 at 11:46 AM
Summit Therapeutics (SMMT) Given a $20.00 Price Target by HC Wainwright AnalystsSummit Therapeutics (SMMT) Given a $20.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 18 at 9:53 AM
Summit Therapeutics (SMMT) Expected to Announce Quarterly Sales of $5.54 MillionSummit Therapeutics (SMMT) Expected to Announce Quarterly Sales of $5.54 Million
www.americanbankingnews.com - April 16 at 4:57 AM
Summit Therapeutics (SMMT) Given Consensus Recommendation of "Buy" by BrokeragesSummit Therapeutics (SMMT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 3:30 AM
Summit Therapeutics (SMMT) Expected to Announce Earnings of -$0.71 Per ShareSummit Therapeutics (SMMT) Expected to Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - April 14 at 1:06 AM
Needham & Company LLC Trims Summit Therapeutics (SMMT) Target Price to $27.00Needham & Company LLC Trims Summit Therapeutics (SMMT) Target Price to $27.00
www.americanbankingnews.com - April 12 at 10:45 AM
Summit Therapeutics (SMMT) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowSummit Therapeutics (SMMT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:16 PM
Summit Therapeutics (SMMT) Posts  Earnings Results, Misses Expectations By $0.34 EPSSummit Therapeutics (SMMT) Posts Earnings Results, Misses Expectations By $0.34 EPS
www.americanbankingnews.com - April 11 at 10:31 AM
Summit Therapeutics (SMMT) Scheduled to Post Earnings on WednesdaySummit Therapeutics (SMMT) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 10 at 8:46 AM
Summit Therapeutics (SMMT) Rating Increased to Hold at Zacks Investment ResearchSummit Therapeutics (SMMT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:23 PM
Summit Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferenceSummit Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
globenewswire.com - April 5 at 8:45 AM
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual MeetingSummit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 5 at 8:45 AM
 Brokerages Anticipate Summit Therapeutics PLC (SMMT) Will Post Quarterly Sales of $4.91 Million Brokerages Anticipate Summit Therapeutics PLC (SMMT) Will Post Quarterly Sales of $4.91 Million
www.americanbankingnews.com - March 30 at 4:18 AM
Summit Therapeutics (SMMT) Downgraded by Zacks Investment Research to SellSummit Therapeutics (SMMT) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 28 at 10:48 AM
Summit Therapeutics PLC (SMMT) Given Average Rating of "Buy" by BrokeragesSummit Therapeutics PLC (SMMT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 20 at 3:34 AM
Summits Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against ... - GlobeNewswire (press release)Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 10:48 AM
Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against GonorrhoeaSummit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
finance.yahoo.com - March 13 at 10:07 AM
Summit Therapeutics PLC (SMMT) Expected to Post Quarterly Sales of $4.91 MillionSummit Therapeutics PLC (SMMT) Expected to Post Quarterly Sales of $4.91 Million
www.americanbankingnews.com - March 12 at 2:38 AM
Summit Therapeutics (SMMT) Stock Rating Lowered by Zacks Investment ResearchSummit Therapeutics (SMMT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 8 at 6:49 PM
Summit Therapeutics (SMMT) Stock Rating Upgraded by ValuEngineSummit Therapeutics (SMMT) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 3 at 4:13 PM
FY2018 Earnings Forecast for Summit Therapeutics PLC Issued By Oppenheimer (SMMT)FY2018 Earnings Forecast for Summit Therapeutics PLC Issued By Oppenheimer (SMMT)
www.americanbankingnews.com - February 28 at 11:44 AM
 Analysts Expect Summit Therapeutics PLC (SMMT) Will Post Quarterly Sales of $4.89 Million Analysts Expect Summit Therapeutics PLC (SMMT) Will Post Quarterly Sales of $4.89 Million
www.americanbankingnews.com - February 24 at 9:28 AM
Summit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by AnalystsSummit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Summit Therapeutics (SMMT) Receives New Coverage from Analysts at BTIG ResearchSummit Therapeutics (SMMT) Receives New Coverage from Analysts at BTIG Research
www.americanbankingnews.com - February 18 at 10:54 PM
ValuEngine Downgrades Summit Therapeutics (SMMT) to SellValuEngine Downgrades Summit Therapeutics (SMMT) to Sell
www.americanbankingnews.com - February 9 at 11:12 PM
Zacks: Analysts Expect Summit Therapeutics PLC (SMMT) to Post -$0.77 Earnings Per ShareZacks: Analysts Expect Summit Therapeutics PLC (SMMT) to Post -$0.77 Earnings Per Share
www.americanbankingnews.com - February 5 at 3:12 AM
ValuEngine Upgrades Summit Therapeutics (SMMT) to "Hold"ValuEngine Upgrades Summit Therapeutics (SMMT) to "Hold"
www.americanbankingnews.com - February 4 at 1:16 PM
Summit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by BrokeragesSummit Therapeutics PLC (SMMT) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 29 at 3:16 AM
Summit Therapeutic (SMMT) Says Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data from PhaseOut DMD Clinical TrialSummit Therapeutic (SMMT) Says Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data from PhaseOut DMD Clinical Trial
www.streetinsider.com - January 27 at 9:16 AM
Summit Therapeutics (SMMT) Price Target Increased to $30.00 by Analysts at OppenheimerSummit Therapeutics (SMMT) Price Target Increased to $30.00 by Analysts at Oppenheimer
www.americanbankingnews.com - January 26 at 3:48 PM
Summit Therapeutics (SMMT) Rating Reiterated by HC WainwrightSummit Therapeutics (SMMT) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - January 25 at 12:50 PM
Summit Therapeutics plc : Interim 24-Week Data from PhaseOut DMDSummit Therapeutics plc : Interim 24-Week Data from PhaseOut DMD
uk.finance.yahoo.com - January 25 at 8:57 AM
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical TrialEzutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
finance.yahoo.com - January 25 at 8:57 AM
Summit Therapeutics PLC (SMMT) Expected to Announce Quarterly Sales of $4.67 MillionSummit Therapeutics PLC (SMMT) Expected to Announce Quarterly Sales of $4.67 Million
www.americanbankingnews.com - January 21 at 10:56 AM
Summit Therapeutics (SMMT) Upgraded by Zacks Investment Research to "Strong-Buy"Summit Therapeutics (SMMT) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - January 12 at 8:50 AM
Summit Therapeutics to Present at the Biotech Showcase - GlobeNewswire (press release)Summit Therapeutics to Present at the Biotech Showcase - GlobeNewswire (press release)
globenewswire.com - January 9 at 11:09 AM
SunTrust Banks Comments on Summit Therapeutics PLCs FY2018 Earnings (SMMT)SunTrust Banks Comments on Summit Therapeutics PLC's FY2018 Earnings (SMMT)
www.americanbankingnews.com - January 8 at 9:38 AM
Summit Therapeutics (SMMT) Upgraded to Hold by Zacks Investment ResearchSummit Therapeutics (SMMT) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - January 7 at 8:37 AM
SunTrust Robinson Humphrey Starts Summit Therapeutics plc ... - StreetInsider.comSunTrust Robinson Humphrey Starts Summit Therapeutics plc ... - StreetInsider.com
www.streetinsider.com - January 4 at 3:40 PM
Summit Therapeutics PLC (SMMT) Receives Consensus Recommendation of "Hold" from AnalystsSummit Therapeutics PLC (SMMT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 4 at 10:26 AM

SEC Filings

Summit Therapeutics (NASDAQ:SMMT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Summit Therapeutics (NASDAQ:SMMT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Summit Therapeutics (NASDAQ SMMT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.